Yale Bulletin and Calendar

January 11, 2008|Volume 36, Number 14


BULLETIN HOME

VISITING ON CAMPUS

CALENDAR OF EVENTS

IN THE NEWS

BULLETIN BOARD

CLASSIFIED ADS


SEARCH ARCHIVES

DEADLINES

DOWNLOAD FORMS

BULLETIN STAFF


PUBLIC AFFAIRS HOME

NEWS RELEASES

E-MAIL US


YALE HOME PAGE


Findings set stage for prevention of epilepsy

Yale School of Medicine researchers have shown for the first time that it is possible to suppress the development of epilepsy in genetically predisposed animals, a discovery that could open the door to treating epilepsy as a preventable disease.

According to the study published this month in Epilepsia, early treatment of epilepsy-prone rats with the anti-convulsant medication ethosuximide before the onset of seizures led to a marked suppression of seizures both later in life and months after treatment stopped.

“Current treatments for epilepsy may control seizures, but they do nothing to alter the underlying disease,” says Dr. Hal Blumenfeld, associate professor of neurology and lead author of the study. “These findings are important because they set the stage for prevention of epilepsy in genetically susceptible people.”

Epilepsy is a common neurological disorder that affects about 50 million people worldwide. It is characterized by seizures — temporary loss of consciousness or muscular control — that are precipitated by abnormal electrical overload on neurons within the brain.

Using a combination of molecular profiling, electroencephalogram (EEG) recordings and power spectral analysis, Blumenfeld and his colleagues demonstrated that ethosuximide effectively blocked the expression of an epilepsy-associated maladaptive protein within neurons of the brain and reduced the number of seizures in treated animals.

“These findings prove that prevention of epilepsy in people is an achievable goal,” Blumenfeld says. “Strategies for primary prevention of diseases like epilepsy will be increasingly important as genetic prediction of these diseases improves.”

He adds that the results must be confirmed in other animals and with other medications before moving on to human treatment trials.

By Jacqueline Weaver


T H I SW E E K ' SS T O R I E S

University is increasing payout from endowment

Stern named to third term as dean of School of Architecture

Findings set stage for prevention of epilepsy

Antibody may delay development of diabetes

Scientists determine intricate process used in assembly . . .

Mutant gene identified as ‘villain’ in hardening of the arteries

Researchers find gene that protects newborns . . .

Yale Rep stages the world premiere of ‘The Evildoers’

Exhibit reveals the ways in which mathematics . . .

Advocates for universal preschools win Grawemeyer Award . . .

Two medical school researchers win awards . . .

Lewis Walpole Library celebrates re-opening with exhibition

Peabody to honor Martin Luther King Jr.’s legacy with festival

Stanton Wheeler, was musician, master, sociologist and sports fan

Change of venue for Waith memorial

Campus Notes


Bulletin Home|Visiting on Campus|Calendar of Events|In the News

Bulletin Board|Classified Ads|Search Archives|Deadlines

Bulletin Staff|Public Affairs|News Releases| E-Mail Us|Yale Home